BioCentury | Jun 22, 2017
Targets & Mechanisms

Exosomes deliver

...serum biomarkers for early identification and stratification of PDAC patients, in pivotal trials. In addition, Precision Biologics Inc....
...Santa Monica, Calif. Massachusetts General Hospital (MGH), Boston, Mass. Orum Therapeutics Inc., Daejeon, South Korea Precision Biologics Inc....
BioCentury | Jan 13, 2016
Politics & Policy

Coalition aims for cancer MoonShot

...NantWorks LLC (Los Angeles, Calif.), Etubics Corp. (Seattle, Wash.), Altor BioScience Corp. (Miramar, Fla.) and Precision Biologics Inc....
BioCentury | Oct 26, 2015
Financial News

Precision Biologics completes venture financing

Precision Biologics Inc. , Dallas, Texas Business: Cancer, Diagnostic Date completed: 2015-10-19 Type: Venture financing Raised: $50 million Investor: NantWorks WIR Staff...
BioCentury | Oct 20, 2015
Financial News

NantWorks invests $50M in Precision Biologics

...invested $50 million in Precision Biologics Inc. (Dallas, Texas), giving it a majority stake in the company. Precision Biologics...
...It has Orphan Drug designation from FDA to treat pancreatic cancer. Evolution Venture Partners was Precision Biologics'...
BioCentury | Jun 8, 2015
Clinical News

Ensituximab: Completed Phase II enrollment

...an open-label, U.S. Phase II trial evaluating 3 mg/kg IV NPC-1C once every 2 weeks. Precision Biologics Inc....
BioCentury | Apr 28, 2014
Clinical News

NEO-102: Interim Phase I/IIa data

...stable disease. Of the 16 patients treated, 13 are still alive. Based on the data, Precision Biologics...
...patients. Data were presented at the American Association for Cancer Research meeting in San Diego. Precision Biologics...
...reformulation of the company's NEO-101 ( NPC-1C , ensituximab) with improved "productivity, stability and safety." Precision Biologics Inc....
BioCentury | Jun 10, 2013
Clinical News

Ensituximab: Phase I/IIa data

...was well tolerated with no dose-limiting toxicities (DLTs) reported (see BioCentury, April 22). Last September, Precision Biologics...
...including ensituximab, of Neogenix Oncology Inc. (Great Neck, N.Y.), which filed for bankruptcy last year. Precision Biologics Inc....
BioCentury | Apr 22, 2013
Clinical News

Ensituximab: Phase I data

...presented at the American Society of Clinical Oncology meeting in Chicago in June. Last September, Precision Biologics...
...including ensituximab, of Neogenix Oncology Inc. (Great Neck, N.Y.), which filed for bankruptcy last year. Precision Biologics Inc....
Items per page:
1 - 8 of 8
BioCentury | Jun 22, 2017
Targets & Mechanisms

Exosomes deliver

...serum biomarkers for early identification and stratification of PDAC patients, in pivotal trials. In addition, Precision Biologics Inc....
...Santa Monica, Calif. Massachusetts General Hospital (MGH), Boston, Mass. Orum Therapeutics Inc., Daejeon, South Korea Precision Biologics Inc....
BioCentury | Jan 13, 2016
Politics & Policy

Coalition aims for cancer MoonShot

...NantWorks LLC (Los Angeles, Calif.), Etubics Corp. (Seattle, Wash.), Altor BioScience Corp. (Miramar, Fla.) and Precision Biologics Inc....
BioCentury | Oct 26, 2015
Financial News

Precision Biologics completes venture financing

Precision Biologics Inc. , Dallas, Texas Business: Cancer, Diagnostic Date completed: 2015-10-19 Type: Venture financing Raised: $50 million Investor: NantWorks WIR Staff...
BioCentury | Oct 20, 2015
Financial News

NantWorks invests $50M in Precision Biologics

...invested $50 million in Precision Biologics Inc. (Dallas, Texas), giving it a majority stake in the company. Precision Biologics...
...It has Orphan Drug designation from FDA to treat pancreatic cancer. Evolution Venture Partners was Precision Biologics'...
BioCentury | Jun 8, 2015
Clinical News

Ensituximab: Completed Phase II enrollment

...an open-label, U.S. Phase II trial evaluating 3 mg/kg IV NPC-1C once every 2 weeks. Precision Biologics Inc....
BioCentury | Apr 28, 2014
Clinical News

NEO-102: Interim Phase I/IIa data

...stable disease. Of the 16 patients treated, 13 are still alive. Based on the data, Precision Biologics...
...patients. Data were presented at the American Association for Cancer Research meeting in San Diego. Precision Biologics...
...reformulation of the company's NEO-101 ( NPC-1C , ensituximab) with improved "productivity, stability and safety." Precision Biologics Inc....
BioCentury | Jun 10, 2013
Clinical News

Ensituximab: Phase I/IIa data

...was well tolerated with no dose-limiting toxicities (DLTs) reported (see BioCentury, April 22). Last September, Precision Biologics...
...including ensituximab, of Neogenix Oncology Inc. (Great Neck, N.Y.), which filed for bankruptcy last year. Precision Biologics Inc....
BioCentury | Apr 22, 2013
Clinical News

Ensituximab: Phase I data

...presented at the American Society of Clinical Oncology meeting in Chicago in June. Last September, Precision Biologics...
...including ensituximab, of Neogenix Oncology Inc. (Great Neck, N.Y.), which filed for bankruptcy last year. Precision Biologics Inc....
Items per page:
1 - 8 of 8